The Genesis Labs Diarrhea Pathogen Panel uses polymerase chain reaction (PCR) technology to test for twenty-six gastroenteritis-associated pathogens. A single sample and a single test provide unparalleled clinical certainty and patient care. As a result, the Genesis Labs Expanded GI Panel provides targeted therapies that do the following:

• Campylobacter spp.
• Campylobacter jejuni
• Toxigenic Clostridium difficile
• Enteroaggregative E. coli (EAEC)
• Enteropathogenic E. coli (EPEC)
• Enterotoxigenic E. coli (ETEC)
• Shigella/Enteroinvasive E. coli (EIEC)
• Plesiomonas shigelloides
• Salmonella spp.
• Shiga-like toxin-producing E. coli (STEC)
• including serotype O157
• Vibrio spp.
• Vibrio cholerae
• Vibrio parahaemolyticus
• Yersinia enterocolitica

• Adenovirus F40/41
• Astrovirus
• Norovirus GI
• Norovirus GII
• Rotavirus A
• Rotavirus B
• Rotavirus C
• Sapovirus I, II, IV Combination
• Sapovirus V

• Cryptosporidium
• Entamoeba histolytica
• Giardia lamblia

• Vancomycin Resistance (vanA)
• Vancomycin Resistance (vanB)
• Nitroimidazole Resistance (nimA)
• Nitroimidazole Resistance (nimD)
• Quinolone and Fluoroquinolone Resistance (qnrA)
• Quinolone and Fluoroquinolone Resistance (qnrB)
• Erythromycin Resistance (ermA)
• Erythromycin Resistance (ermB)
• Trimethoprim-Sulfamethoxazole Resistance (dfrA1)
• Trimethoprim-Sulfamethoxazole Resistance (dfrA5)
• Yersinia enterocolitica

• Reflex to active Toxin detection by EIA for positive samples

• Cryptosporidium (C.hominis and C.parvum)
• Entamoeba histolytica
• Giardia lamblia